People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Beam Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $218.6M | $4.8B | 2018 |
| Semma Therapeutics, Inc. | — | Biotechnology | Series D+ | $129.3M | $4.7B | 2017 |
| BNA Chicago LLC | — | Other | Seed | $1.9M | $35.3M | 2011 |
MARK FISHMAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MARK FISHMAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| STEPHEN KNIGHT | 2 | 6 |
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Fred Cohen | 1 | 12 |
| Todd Foley | 1 | 12 |
| Robert Nelson | 1 | 7 |
| John Evans | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| Michael Yi | 1 | 4 |
| Robert Millman | 1 | 3 |
| Mitchell Finer | 1 | 3 |
| Daniel Auerbach | 1 | 3 |
| Feng Zhang | 1 | 3 |
| Elizabeth Stoner | 1 | 2 |
| Jim Scopa | 1 | 2 |
| Bastiano Sanna | 1 | 2 |
| William Sahlman | 1 | 2 |
| Mitch Finer | 1 | 2 |
| Kingsley Taft | 1 | 1 |
| CAROLE HO | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.